Printer Friendly

Probiotic for periodontal disease.

Thirty patients with chronic periodontitis and moderately deep pockets were treated with scaling and root planing and were randomly assigned to receive, in double-blind fashion, probiotic lozenges twice a day (morning and evening after toothbrushing) or placebo lozenges for 3 weeks. The probiotic lozenges (Prodentis; BioGaia, Lund, Sweden) contained at least 108 colony-forming units each of Lactobacillus reuterl strains DSM17938 and ATCC PTA 5289 (this information was not mentioned in the study, but came from a personal communication with one of the authors). Evaluations were performed at baseline and on days 21, 90, 180, and 360. Compared with placebo, probiotic treatment resulted in significant improvements in plaque index, gingival index, bleeding on probing, probing depth, and attachment gain at every time point. Biochemical studies on gingival crevicular fluid revealed a reduction in inflammatory markers in the probiotic group.

Comment: This study demonstrates that the use of lozenges containing L. reuteri was beneficial as an adjunct to scaling and root planing in patients with chronic periodontitis and moderately deep pockets. The beneficial effect of the probiotic lozenges persisted long after the treatment was discontinued. Although the mechanism of action is not certain, it may be related to an alteration of the oral bacterial flora.

Ince G et al. Clinical and biochemical evaluation of lozenges containing Lactobacillus reuteri as an adjunct to non-surgical periodontal therapy in chronic periodontitis. J Periodontol. 2015;86:746-754.

by Alan R. Gaby, MD

COPYRIGHT 2015 The Townsend Letter Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Literature Review & Commentary
Author:Gaby, Alan R.
Publication:Townsend Letter
Article Type:Brief article
Geographic Code:1USA
Date:Dec 1, 2015
Previous Article:Iron deficiency in patients with coronary artery disease.
Next Article:Curcumin for ulcerative colitis.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters